+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04617522

Phase 1 Study to Find the Right Starting Dose of Sacituzumab Govitecan for Adults with Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Led by Gilead Sciences · Updated on 2026-06-02

30

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying sacituzumab govitecan-hziy to understand its safety and dosing in adults with advanced or metastatic solid tumors who also have moderate liver problems. This phase 1 study focuses on participants with varying liver function to find appropriate dosing while monitoring side effects and drug behavior in the body. Participants with moderate liver impairment will receive increasing doses of sacituzumab govitecan-hziy on Days 1 and 8, starting from 5 mgkg and potentially increasing to 10 mgkg if safe. Those with normal liver function will receive a fixed dose of 10 mgkg on the same schedule. After completing the study treatment, participants benefiting from the drug may continue treatment in a related extension study sponsored by Gilead Sciences. Throughout the study, participants will be closely monitored for side effects, serious adverse events, and dose-limiting toxicities up to Day 38. Blood samples will be collected to study drug levels and immune responses on specific days. The study aims to gather detailed safety and pharmacokinetic data to guide future dosing recommendations, with participation lasting through the initial treatment and potential rollover study.

CONDITIONS

Brief Title

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here